

CIN: L15142RJ1991PLC006353

# SARDA PROTEINS LTD.

Date: 19<sup>th</sup> October, 2022

To,  
BSE Limited,  
Phiroze Jeejeebhoy Towers,  
Dalal Street,  
Mumbai- 400001 (Maharashtra)

(BY BSE LISTING CENTRE)

**Sub: Disclosure pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations").**

**Ref.: Sarda Proteins Ltd, Scrip Code: 519242, Security ID: SRDAPRT.**

Dear Sir /Ma'am,

In accordance with Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are submitting herewith the Un-audited Financial Results of the Company for the quarter and half year ended on 30<sup>th</sup> September, 2022 along with the Statement of Assets and Liabilities as on 30<sup>th</sup> September, 2022 and Statement of Cash Flow for the half year ended on 30<sup>th</sup> September, 2022 and Limited Review Report thereon.

You are requested to kindly take the same on record.

Thanking You,  
Yours Faithfully

**FOR SARDA PROTEINS LTD**

**For SARDA PROTEINS LTD,**



**Company Secretary**

**AMIT KUMAR MODI  
COMPANY SECRETARY &  
COMPLIANCE OFFICER  
M. NO.: A29371**

Encl: a/a

**Reg. Office:** B-536-537, Matsya Industrial Area, Alwar- 301030 (Rajasthan)

**Corp. office:** Inside Data Ingenious Global Limited, Station Road, Durgapura, Jaipur-302018 (Rajasthan)

**Contact No.:** +91-7737822222; **E Mail:** sardaproteins@yahoo.com; **Web:** www.sardaproteins.com

# SARDA PROTEINS LTD

Reg. Off: B-536-537, Matsya Industrial Area, Alwar-301030 (Rajasthan)  
 Phone: +91 7737822222, EMail: sardaproteins@yahoo.com, website: www.sardaproteins.com  
 CIN: L15142RJ1991PLC006353

## STANDALONE UNAUDITED RESULTS FOR THE QUARTER AND HALF YEAR ENDED ON 30TH SEPTEMBER 2022

Rs.in Lakhs

S. No.	Particulars	Quarter ended			Half Year ended		Year ended
		30.09.2022	30.06.2022	30.09.2021	30.09.2022	30.09.2021	31.03.2022
		Un-Audited	Un-Audited	Un-Audited	Un-Audited	Un-Audited	Audited
I.	Revenue from Operations	279.21	-	74.58	279.21	144.34	1,075.98
II.	Other Income	2.48	5.17	2.54	7.65	4.64	8.54
III.	<b>Total Income (I+II)</b>	<b>281.69</b>	<b>5.17</b>	<b>77.12</b>	<b>286.86</b>	<b>148.98</b>	<b>1,084.52</b>
IV.	Expenses:						
	Cost of Material Consumed		-	-	-	-	-
	Purchase of Stock -in- Trade	275.57	-	73.58	275.57	143.33	1,028.63
	Changes in Inventories (Finished Goods, WIP, Stock-in-Trade)		-	-	-	-	-
	Employee Benefit Expenses	3.31	3.44	2.87	6.75	6.55	12.57
	Finance Cost		-	0.02	-	0.02	0.02
	Depreciation and Amortisation Expenses		-	0.02	-	0.04	0.05
	Other expenses	2.54	1.51	3.02	4.05	3.02	7.73
	<b>Total Expenses (IV)</b>	<b>281.42</b>	<b>4.95</b>	<b>79.51</b>	<b>286.37</b>	<b>152.96</b>	<b>1,049.00</b>
V.	Profit/(Loss) before Exceptional and Extraordinary Items and Tax (III-IV)	0.27	0.22	(2.39)	0.49	(3.98)	35.52
VI.	Exceptional Items		-	-	-	-	0.24
VII.	Profit/(Loss) before Tax (V-VI)	0.27	0.22	(2.39)	0.49	(3.98)	35.28
VIII.	Tax Expense:						
	(1) Current Tax		-	-	-	-	-
	(2) Deferred Tax		-	-	-	-	4.53
IX.	Profit/(Loss) for the period from Continuing Operations (VII-VIII)	0.27	0.22	(2.39)	0.49	(3.98)	30.75
X.	Profit/(Loss) from Discontinued Operations	-	-	-	-	-	-
XI.	Tax Expenses of Discontinued Operations		-	-	-	-	-
XII.	Profit/(Loss) from Discontinued Operations (after tax) (X-XI)	-	-	-	-	-	-
XIII.	Profit/(Loss) for the Period (IX+XII)	0.27	0.22	(2.39)	0.49	(3.98)	30.75
XIV.	Other Comprehensive Income						
	A (i) Items will not be reclassified to Profit or Loss	-	-	-	-	-	-
	(ii) Income Tax relating to items that will not be reclassified to Profit or Loss	-	-	-	-	-	-
	B (i) Items will be reclassified to Profit or Loss	-	-	-	-	-	-
	(ii) Income Tax relating to items that will be reclassified to Profit or Loss	-	-	-	-	-	-
XV.	<b>Total Comprehensive Income for the period (XIII+XIV)(Comprising Profit (Loss) and other Comprehensive Income for the period)</b>	<b>0.27</b>	<b>0.22</b>	<b>(2.39)</b>	<b>0.49</b>	<b>(3.98)</b>	<b>30.75</b>
XVI.	Paid Up Equity Share Capital, Equity Shares Of Face Value Rs. 10 each	172.59	172.59	172.59	172.59	172.59	172.59
XVII.	Earnings per Equity Share						
	(1) Basic	0.02	0.01	(0.14)	0.03	(0.23)	1.78
	(2) Diluted	0.02	0.01	(0.14)	0.03	(0.23)	1.78



# SARDA PROTEINS LTD

Reg. Off: B-536-537, Matsya Industrial Area, Alwar-301030 (Rajasthan)


Phone: +91 7737822222, EMail: sardaproteins@yahoo.com, website: www.sardaproteins.com

CIN: L15142RJ1991PLC006353

## STATEMENT OF ASSETS AND LIABILITIES AS AT 30TH SEPTEMBER 2022

Rs in Lakhs

Particulars	Six Months ended		Year ended
	30.09.2022	30.09.2021	31.03.2022
	Un-Audited	Un-Audited	Audited
<b>A. ASSETS</b>			
<b>1. Non-Current Assets</b>			
a) Property, Plant and Equipment	0.01	0.50	0.01
b) Capital work in progress	-	-	-
c) Investment Property	-	-	-
d) Goodwill	-	-	-
e) Other Intangible Assets	-	-	-
f) Intangible Assets under Development	-	-	-
g) Biological Assets other than bearer plants	-	-	-
h) Financial Assets			
i) Investments	0.13	0.13	0.13
ii) Trade Receivables	-	-	-
iii) Loans	-	-	-
i) Deferred Tax Assets (net)	18.09	22.62	18.09
j) Other non-current Assets	-	-	-
<b>2. Current Assets</b>			
a) Inventories	-	-	-
b) Financial Assets			
i) Investments	-	-	-
ii) Trade Receivables	18.31	82.87	20.80
iii) Cash and Cash Equivalents	0.25	0.03	32.27
iv) Bank Balances and other than (iii) above	2.51	2.03	0.31
v) Loans	205.00	97.36	173.65
v) Others	-	-	-
c) Current Tax Assets (net)	-	-	-
d) Other Current Assets	-	-	-
<b>Total Assets</b>	<b>244.30</b>	<b>205.54</b>	<b>245.26</b>
<b>B. EQUITY AND LIABILITIES</b>			
<b>1. Equity</b>			
a) Equity Share Capital	250.45	250.45	250.45
b) Other Equity	(11.31)	(48.56)	(11.80)
<b>2. Liabilities</b>			
<b>Non current Liabilities</b>			
a) Financial Liabilities			
i) Borrowings	-	-	-
ii) Trade Payables			
A) Total Outstanding dues to MSEs	-	-	-
B) Total Outstanding dues to Creditors other than MSEs	-	-	-
iii) Other Financial Liabilities	-	-	-
b) Provisions	3.00	1.42	3.00
c) Deferred Tax Liabilities (net)	-	-	-
d) Other Non Current Liabilities	-	-	-
<b>Current Liabilities</b>			
a) Financial Liabilities			
i) Borrowings	-	-	-
ii) Trade Payables			
A) Total Outstanding dues to MSEs	-	-	-
B) Total Outstanding dues to Creditors other than MSEs	1.33	0.08	-
iii) Other Financial Liabilities	-	-	-
b) Other Current Liabilities	0.83	(1.66)	3.61
c) Provisions	-	2.09	-
d) Current Tax Liabilities (net)	-	1.72	-
<b>Total Equity and Liabilities</b>	<b>244.30</b>	<b>205.54</b>	<b>245.26</b>



# SARDA PROTEINS LTD

Reg. Off: B-536-537, Matsya Industrial Area, Alwar-301030 (Rajasthan)  
 Phone: +91 7757822222, EMail: sardaproteins@yahoo.com website: www.sardaproteins.com  
 CTN: L15142RJ1991PLC006353

## CASH FLOW STATEMENT FOR THE HALF YEAR ENDED ON 30TH SEPTEMBER 2022


Rs in Lakhs

	Particulars	Six Months ended		Year ended
		30.09.2022	30.09.2021	31.03.2022
		Un-Audited	Un-Audited	Audited
	<b>CASH FLOW FROM OPERATING ACTIVITIES</b>			
	Net Profit before Tax and Extraordinary Items	0.49	(3.98)	35.28
A.	<b>ADJUSTMENT FOR:</b>			
	Depreciation	-	0.04	0.05
	Interest Received	(7.65)	(4.64)	(8.54)
	Profit on Sale of Investment	-	-	-
	Dividend	-	-	-
	(Profit) / Loss on sale of Fixed Assets	-	-	0.24
	Interest Paid	-	-	0.02
	<b>Operating Profit/(Loss) before Working Capital Charges</b>	<b>(7.16)</b>	<b>(8.58)</b>	<b>27.05</b>
	<b>ADJUSTMENT FOR:</b>			
	Trade and other Receivables	(28.86)	(3.61)	(17.83)
	Inventories	-	-	-
	Trade & other Payables	(1.45)	(1.78)	1.21
	Other Non Current Assets	-	(2.00)	-
	<b>Cash Generated from Operations</b>	<b>(37.47)</b>	<b>(15.97)</b>	<b>10.43</b>
	Direct Taxes Paid	-	-	-
	<b>Net Cash from Operating Activities</b>	<b>(37.47)</b>	<b>(15.97)</b>	<b>10.43</b>
B.	<b>CASH FLOW FROM INVESTING ACTIVITIES</b>			
	Capital Expenditure	-	-	-
	Sale of Fixed Assets	-	-	-
	Profit / (Loss) on sale of Fixed Assets	-	-	0.24
	Profit on sale of Investment	-	-	-
	Sale of Investment	-	-	-
	Interest Received	7.65	4.64	8.54
	Dividend Received	-	-	-
	<b>Net Cash Received from Investing Activities</b>	<b>7.65</b>	<b>4.64</b>	<b>8.78</b>
C.	<b>CASH FLOW FROM FINANCING ACTIVITIES</b>			
	Proceeds from Long Term Borrowings	-	-	-
	Proceeds from Short Term Borrowings	-	-	-
	Interest Paid	-	-	(0.02)
	<b>Net Cash Inflow/ (Outflow) from Financing Activities</b>	<b>-</b>	<b>-</b>	<b>(0.02)</b>
	<b>Net Cash Increase/(Decrease) in Cash and Cash Equivalents (A+B+C)</b>	<b>(29.82)</b>	<b>(11.33)</b>	<b>19.19</b>
	Cash & Cash Equivalents (Opening)	32.58	13.39	13.39
	<b>Cash &amp; Cash Equivalents (Closing)</b>	<b>2.76</b>	<b>2.06</b>	<b>32.58</b>

**Notes:**

1. The above results were approved by Audit Committee and Board of Directors in their meeting held on 19th October 2022.
2. Equity Share Capital includes RS. 77.86 Lakhs as Share Forfeiture Account.
3. Segment Results as per AS is not applicable as dealing in only one segment i.e. " Agro Products".
4. No Investor Complaints were received during the quarter ended 30-Sep-2022 nor any pending as on 01-Oct-2022.
5. Figures for the previous period have been regrouped wherever considered necessary so as to confirm to the classification of the current period.

on behalf of the Board  
Sarda Proteins Ltd



Deepak Data (DIN: 01672415)  
Managing Director

UDIN 7 22072854BAG1DDH4850

Place: Jaipur  
Date: 19-Oct-2022





*Khetawat Agarwal & Co.*  
Chartered Accountants

**Limited Review Report**  
**Unaudited Standalone Quarterly Results**



To  
The Board of Directors  
**Sarda Proteins Ltd**

We have reviewed the accompanying statement of unaudited financial results of **SARDA PROTEINS LTD** for the Quarter and Half Year ended on 30<sup>th</sup> September, 2022. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Khetawat Agarwal & Co.  
Chartered Accountants  
FRN: 003960C

  
  
M.L. Agarwal  
Partner  
M. No.: 072854

UDIN : २२०२२८५४BA८००H४८५०

Place : Jaipur  
Date : 19.10.2022